Cargando…

Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial

OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on‐the‐road driving performance in participants with narcolepsy. METHODS: In this randomised, double‐blind, placebo‐controlled, crossover study, driving performance during a 1 h on‐road driving te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vinckenbosch, Frederick, Lammers, Gert Jan, Overeem, Sebastiaan, Chen, Dan, Wang, Grace, Carter, Lawrence P., Zhou, Kefei, Ramaekers, Johannes G., Vermeeren, Annemiek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078175/ https://www.ncbi.nlm.nih.gov/pubmed/36420633 http://dx.doi.org/10.1002/hup.2858

Ejemplares similares

Effects of solriamfetol on on‐the‐road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea
por: Vinckenbosch, Frederick, et al.
Publicado: (2022)

Comparing objective wakefulness and vigilance tests to on‐the‐road driving performance in narcolepsy and idiopathic hypersomnia
por: Bijlenga, Denise, et al.
Publicado: (2021)

Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions
por: Devine, Jaime K., et al.
Publicado: (2022)

A randomized study of solriamfetol for excessive sleepiness in narcolepsy
por: Thorpy, Michael J., et al.
Publicado: (2019)

Solriamfetol for the Use of Narcolepsy: A Systematic Review
por: Iturburu, Alisson, et al.
Publicado: (2022)

P148 Solriamfetol Titration & AdministRaTion (START): Dosing and titration strategies in patients with narcolepsy starting solriamfetol
por: Thorpy, M, et al.
Publicado: (2021)

Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea
por: Malhotra, Atul, et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
por: Zomorodi, Katie, et al.
Publicado: (2020)

A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation
por: Quaedackers, Laury, et al.
Publicado: (2020)

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives
por: Abad, Vivien C
Publicado: (2021)

Enhanced food-related responses in the ventral medial prefrontal cortex in narcolepsy type 1
por: van Holst, Ruth Janke, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor
por: Carter, Lawrence P, et al.
Publicado: (2018)

Publisher Correction: Enhanced food-related responses in the ventral medial prefrontal cortex in narcolepsy type 1
por: van Holst, Ruth Janke, et al.
Publicado: (2019)

Alcohol calibration of tests measuring skills related to car driving
por: Jongen, Stefan, et al.
Publicado: (2014)

Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment
por: Vinckenbosch, F. R. J., et al.
Publicado: (2020)

Recognizing the Symptom Spectrum of Narcolepsy to Improve Timely Diagnosis: A Narrative Review
por: Quaedackers, Laury, et al.
Publicado: (2021)

Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1
por: van der Hoeven, Adrienne Elisabeth, et al.
Publicado: (2022)

On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics
por: Leufkens, T. R. M., et al.
Publicado: (2014)

Sensitivity and Validity of Psychometric Tests for Assessing Driving Impairment: Effects of Sleep Deprivation
por: Jongen, Stefan, et al.
Publicado: (2015)

Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019)

Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning
por: Zhang, Zhongxing, et al.
Publicado: (2018)

P147 Solriamfetol Titration & AdministRaTion (START): Characteristics of patients with obstructive sleep apnoea (OSA) and prescriber rationale for starting treatment with solriamfetol
por: Singh, H, et al.
Publicado: (2021)

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2018)

Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
por: Vermeeren, Annemiek, et al.
Publicado: (2020)

Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study
por: Leufkens, T. R. M., et al.
Publicado: (2014)

Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial
por: Weaver, Terri E., et al.
Publicado: (2020)

Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation
por: Al-Rifai, Nafisah, et al.
Publicado: (2023)

An explorative approach to understanding individual differences in driving performance and neurocognition in long‐term benzodiazepine users
por: Vinckenbosch, Frederick R. J., et al.
Publicado: (2021)

High frequency repetitive transcranial magnetic stimulation over the motor cortex: No diagnostic value for narcolepsy/cataplexy
por: Overeem, S., et al.
Publicado: (2007)

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol
por: van der Sluiszen, N. N. J. J. M., et al.
Publicado: (2016)

Reduced Numbers of Corticotropin‐Releasing Hormone Neurons in Narcolepsy Type 1
por: Shan, Ling, et al.
Publicado: (2022)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Narcolepsy risk loci outline role of T cell autoimmunity and infectious triggers in narcolepsy
por: Ollila, Hanna M., et al.
Publicado: (2023)

Therapeutic Strategies for Mitigating Driving Risk in Patients with Narcolepsy
por: McCall, Catherine A, et al.
Publicado: (2020)

Assessing sleep-wake survival dynamics in relation to sleep quality in a placebo-controlled pharmacological intervention study with people with insomnia and healthy controls
por: Hermans, Lieke W. A., et al.
Publicado: (2020)

Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis
por: Zhang, Zhongxing, et al.
Publicado: (2022)

Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation
por: Koopmans, Ingrid, et al.
Publicado: (2023)

ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy
por: Faraco, Juliette, et al.
Publicado: (2013)

Narcolepsy
por: Maclachlan, T. Kay
Publicado: (1930)

Narcolepsy
Publicado: (1929)

Cannot write session to /tmp/vufind_sessions/sess_f8f1vb77ntcnmliv86s3ghouo2